Sign up for our daily briefing
Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.
Sign up for Axios Pro Rata
Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Want a daily digest of the top Austin news?
Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.
Want a daily digest of the top Atlanta news?
Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.
Want a daily digest of the top Philadelphia news?
Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.
Want a daily digest of the top Chicago news?
Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Want a daily digest of the top DC news?
Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.
Photo: Rafael Henrique/SOPA Images/LightRocket via Getty Images
GlaxoSmithKline and Sanofi announced on Friday that their coronavirus vaccine program would be delayed until late 2021 in order to improve immune response in older adults.
Why it matters: It's a blow to hopes that the U.S. will have an array of vaccines available for distribution by early 2021. The Trump administration's Operation Warp Speed paid the companies $2.1 billion over the summer to cover some manufacturing costs and purchase an initial batch of 100 million doses.
The state of play: GlaxoSmithKline and Sanofi said they plan to launch another study in February that will include comparing its vaccines to an authorized one. If the results are promising, Phase 3 trials — which were scheduled to begin next month — could start in the second quarter of next year, moving the vaccine's possible availability to the third or fourth quarter.
- The companies said "interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years."
- "Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups," they added.
- The new study will receive support from Operation Warp Speed and the Biomedical Advanced Research and Development Authority.
The big picture: At the moment, only Pfizer's and Moderna's vaccines await an emergency use authorization (EUA) from the Food and Drug Administration.
- An FDA advisory panel on Thursday recommended that the agency proceed with issuing an EUA, which could come as soon as this weekend.
- Earlier this week, it was revealed that the federal government had declined an offer from Pfizer to purchase more doses, saying it was "confident" they'd receive enough doses from Pfizer and other manufacturers, including Moderna.
What they're saying: "[W]e are disappointed by the delay announced today," Thomas Triomphe, head of Sanofi, said. "We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine."
- "The results of the study are not as we hoped ... It is also clear that multiple vaccines will be needed to contain the pandemic," Roger Connor, president of GlaxoSmithKline Vaccines, said.